Mikulicz’s disease is considered one of the IgG4-related diseases that are characterized by elevated serum IgG4 concentrations and the immunohistochemical finding of IgG4-positive plasma cells. The IgG4-related diseases often exhibit a wide variety of eosinophil infiltration. A 66-year-old male with Mikulicz’s disease developed multiple, nonpruritic, red papules on the left opisthotic region 2 years after diagnosis. A biopsy of the skin lesions revealed follicle-like formation in the dermis and subcutaneous tissue containing nodular lymphocytic infiltration with numerous eosinophils and plasma cells, predominately around venules, mimicking angiolymphoid hyperplasia with eosinophilia (ALHE). Immunohistochemically, most IgG-expressing plasma cells were positive for IgG4 (IgG4/IgG ratio = 72%). Our patient appeared to have a condition associated with the IgG4-related diseases. Caution should be exercised in diagnosing skin lesions of the IgG4-related diseases, which are confusingly similar in appearance and histology to ALHE.

Keywords:
IgG4-related disease, Plasma cell and eosinophil infiltration, Mikulicz’s disease
1.
Yamamoto M, Takahashi H, Sugai S, Imai K: Clinical and pathological characteristics of Mikulicz’s disease (IgG4-related plasmacytic exocrinopathy). Autoimmun Rev 2005;4:195–200.
2.
Kamisawa T: IgG4-related sclerosing disease. Intern Med 2006;45:125–126.
3.
Sato Y, Ohshima K, Ichimura K, et al: Ocular adnexal IgG4-related disease has uniform clinicopathology. Pathol Int 2008;58:465–470.
4.
Mikulicz J: Über eine eigenartige symmetrische Erkrankung der Tränen- und Mundspeicheldrüsen. Stuttgart Beitr Chir Festschr Theodor Billroth 1892, pp 610–630.
5.
Khosroshahi A, Stone JH: A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol 2011;23:57–66.
6.
Nakano S, Takeda I, Kitamura K, Watahiki H, Iimura Y, Takenaka M: Vanishing tumor of the abdomen in patient with Sjögren’s syndrome. Dig Dis 1978;23:75S–79S.
7.
Kawaguchi K, Koike M, Tsuruta K, Okamoto A, Tabata I, Fujita N: Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. Hum Pathol 1991;22:387–395.
8.
Hamano H, Kawa S, Horiuchi A, et al: High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732–738.
9.
Kitagawa S, Zen Y, Harada K, et al: Abundant IgG44-positive plasma cell infiltration characterizes chronic sclerosing sialadenitis (Kuttner’s tumor). Am J Surg Pathol 2005; 29:783–791.
10.
Takahira M, Kawano M, Zen Y, Minato H, Yamada K, Sugiyama K: IgG4-related chronic sclerosing dacryoadenitis. Arch Ophthalmol 2007;125:1575–1578.
11.
Shimatsu A, Oki Y, Fujisawa I, Sano T: Pituitary and stalk lesions (infundibulo-hypophysitis) associated with immunoglobulin G4-related systemic disease: an emerging clinical entity. Endocr J 2009;56:1033–1041.
12.
Zen Y, Inoue D, Kitao A, et al: IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases. Am J Surg Pathol 2009;33:1886–1893.
13.
Zen Y, Kitagawa S, Minato H, et al: IgG4-positive plasma cells in inflammatory pseudotumor (plasma cell granuloma) of the lung. Hum Pathol 2005;36:710–717.
14.
Zen Y, Kasahara Y, Horita K, et al: Inflammatory pseudotumor of the breast in a patient with a high serum IgG4 level: histologic similarity to sclerosing pancreatitis. Am J Surg Pathol 2005;29:275–278.
15.
Taniguchi T, Kobayashi H, Fukui S, Ogura K, Saiga T, Okamoto M: A case of multifocal fibrosclerosis involving posterior mediastinal fibrosis, retroperitoneal fibrosis, and a left seminal vesicle with elevated serum IgG4. Hum Pathol 2006;37:1237–1239, author reply 1239.
16.
Kamisawa T, Okamoto A, Funata N: Clinicopathological features of autoimmune pancreatitis in relation to elevation of serum IgG4. Pancreas 2005;31:28–31.
17.
Wang WL, Farris AB, Lauwers GY, Deshpande V: Autoimmune pancreatitis-related cholecystitis: a morphologically and immunologically distinctive form of lymphoplasmacytic sclerosing cholecystitis. Histopathology 2009;54:829–836.
18.
Bjornsson E, Chari ST, Smyrk TC, Lindor K: Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007;45:1547–1554.
19.
Zen Y, Harada K, Sasaki M, et al: IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol 2004;28:1193–1203.
20.
Uehara T, Hamano H, Kawakami M, et al: Autoimmune pancreatitis-associated prostatitis: distinct clinicopathological entity. Pathol Int 2008;58:118–125.
21.
Yoshimura Y, Takeda S, Ieki Y, Takazakura E, Koizumi H, Takagawa K: IgG4-associated prostatitis complicating autoimmune pancreatitis. Intern Med 2006;45:897–901.
22.
Hamano H, Kawa S, Ochi Y, et al: Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet 2002;359:1403–1404.
23.
Zen Y, Sawazaki A, Miyayama S, Notsumata K, Tanaka N, Nakanuma Y: A case of retroperitoneal and mediastinal fibrosis exhibiting elevated levels of IgG4 in the absence of sclerosing pancreatitis (autoimmune pancreatitis). Hum Pathol 2006;37:239–243.
24.
Takeda S, Haratake J, Kasai T, Takaeda C, Takazakura E: IgG4-associated idiopathic tubulointerstitial nephritis complicating autoimmune pancreatitis. Nephrol Dial Transplant 2004;19:474–476.
25.
Kasashima S, Zen Y, Kawashima A, Endo M, Matsumoto Y, Kasashima F: A new clinicopathological entity of IgG4-related inflammatory abdominal aortic aneurysm. J Vasc Surg 2009;49:1264–1271, discussion 1271.
26.
Stone JR: Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease. Curr Opin Rheumatol 2011;23:88–94.
27.
Nakamura H, Hisatomi K, Koga T, et al: Successful treatment of a patient with IgG4-related disease with a paravertebral mass lesion. Mod Rheumatol 2011;21:524–527.
28.
Chan SK, Cheuk W, Chan KT, Chan JK: IgG4-related sclerosing pachymeningitis: a previously unrecognized form of central nervous system involvement in IgG4-related sclerosing disease. Am J Surg Pathol 2009;33:1249–1252.
29.
Cheuk W, Yuen HK, Chu SY, Chiu EK, Lam LK, Chan JK: Lymphadenopathy of IgG4-related sclerosing disease. Am J Surg Pathol 2008;32:671–681.
30.
Zen Y, Nakanuma Y: IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2010;34:1812–1819.
31.
Takahashi N, Ghazale AH, Smyrk TC, Mandrekar JN, Chari ST: Possible association between IgG4-associated systemic disease with or without autoimmune pancreatitis and non-Hodgkin lymphoma. Pancreas 2009;38:523–526.
32.
Shiomi T, Yoshida Y, Horie Y, Yamamoto O: Acquired reactive perforating collagenosis with the histological features of IgG4-related sclerosing disease in a patient with Mikulicz’s disease. Pathol Int 2009;59:326–331.
33.
Kakuchi Y, Yamada K, Suzuki Y, et al: IgG4-related skin lesions in a patient with IgG4-related chronic sclerosing dacryoadenitis and sialoadenitis. Intern Med 2011;50:1465–1469.
34.
Cheuk W, Yuen HK, Chan AC, et al: Ocular adnexal lymphoma associated with IgG4+ chronic sclerosing dacryoadenitis: a previously undescribed complication of IgG4-related sclerosing disease. Am J Surg Pathol 2008;32:1159–1167.
35.
Yamada K, Kawano M, Inoue R, et al: Clonal relationship between infiltrating immunoglobulin G4 (IgG4)-positive plasma cells in lacrimal glands and circulating IgG4-positive lymphocytes in Mikulicz’s disease. Clin Exp Immunol 2008;152:432–439.
36.
Sato Y, Kojima M, Takata K, et al: Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman’s disease. Mod Pathol 2009;22:589–599.
37.
Shimizu I, Nasu K, Sato K, et al: Lymphadenopathy of IgG4-related sclerosing disease: three case reports and review of literature. Int J Hematol 2010;92:751–756.
38.
Oh HC, Kim JG, Kim JW, et al: Early bile duct cancer in a background of sclerosing cholangitis and autoimmune pancreatitis. Intern Med 2008;47:2025–2028.
39.
Kamisawa T, Chen PY, Tu Y, et al: Pancreatic cancer with a high serum IgG4 concentration. World J Gastroenterol 2006;12:6225–6228.
40.
Khosroshahi A, Stone JH: Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol 2011;23:67–71.
41.
Topazian M, Witzig TE, Smyrk TC, et al: Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2008;6:364–366.
42.
Khosroshahi A, Bloch DB, Deshpande V, Stone JH: Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010;62:1755–1762.
43.
Wolf R, Tuzun B, Tuzun Y: Dapsone: unapproved uses or indications. Clin Dermatol 2000;18:37–53.
44.
Wakabayashi M, Fujimoto N, Uenishi T, Danno K, Tanaka T: A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory bowel disease. Dermatology 2011;222:231–235.
45.
Strehl JD, Hartmann A, Agaimy A: Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol 2011;64:237–243.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.